---
title: "Fulgent Genetics | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 84.07 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264865710.md"
datetime: "2025-11-07T12:17:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264865710.md)
  - [en](https://longbridge.com/en/news/264865710.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264865710.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264865710.md) | [繁體中文](https://longbridge.com/zh-HK/news/264865710.md)


# Fulgent Genetics | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 84.07 M

Revenue: As of FY2025 Q3, the actual value is USD 84.07 M, beating the estimate of USD 81.43 M.

EPS: As of FY2025 Q3, the actual value is USD -0.21, beating the estimate of USD -0.54.

EBIT: As of FY2025 Q3, the actual value is USD -23.2 M.

### Laboratory Services

-   **Revenue**: $83.9 million for the three months ended September 30, 2025, and $239.2 million for the nine months ended September 30, 2025.
-   **Cost of Revenue**: $46.9 million for the three months ended September 30, 2025, and $135.8 million for the nine months ended September 30, 2025.
-   **Gross Profit**: $37.0 million for the three months ended September 30, 2025, and $103.4 million for the nine months ended September 30, 2025.
-   **Operating Expenses**: $50.9 million for the three months ended September 30, 2025, and $153.2 million for the nine months ended September 30, 2025.
-   **Operating Loss**: - $15.4 million for the three months ended September 30, 2025, and - $54.9 million for the nine months ended September 30, 2025.

### Therapeutic Development

-   **Revenue**: $0.1 million for the three months ended September 30, 2025, and $0.1 million for the nine months ended September 30, 2025.
-   **Cost of Revenue**: Insignificant for the three and nine months ended September 30, 2025.
-   **Gross Profit**: Insignificant for the three and nine months ended September 30, 2025.
-   **Operating Expenses**: $6.8 million for the three months ended September 30, 2025, and $18.1 million for the nine months ended September 30, 2025.
-   **Operating Loss**: - $6.0 million for the three months ended September 30, 2025, and - $15.1 million for the nine months ended September 30, 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: Fulgent Genetics, Inc. aims to transform from a genomic diagnostic business into a fully integrated precision medicine company. The company plans to continue investing in its laboratory services and therapeutic development segments to drive growth and improve margins.
-   **Non-Core Business**: The company completed the acquisition of ANP Technologies, Inc. in July 2025, which is expected to enhance its control over the development and commercialization of related therapeutic candidates.
-   **Priority**: The company expects to incur more operating expenses and use more cash in operating activities in the coming quarters as a result of planned and ongoing clinical trials for FID-007 and FID-022, and as it continues to invest resources to grow its laboratory services business.

### Related Stocks

- [Fulgent Genetics, Inc. (FLGT.US)](https://longbridge.com/en/quote/FLGT.US.md)

## Related News & Research

- [Cintas (CTAS) Valuation Check After Q3 Results And Higher Fiscal 2026 Guidance](https://longbridge.com/en/news/281225115.md)
- [Nike Takes 'Intentional' Hit To Clear 'Unhealthy Inventory' In Q3 As CEO Eyes Turnaround By Year-End](https://longbridge.com/en/news/281362844.md)
- [Nike Delivers Q3 Earnings Beat As Turnaround Progresses, Shares Slide](https://longbridge.com/en/news/281243092.md)
- [Nike Q3 revenue flat, net income down 35% but beats estimates amid turnaround](https://longbridge.com/en/news/281239071.md)
- [Cintas' Fiscal Q3 Beat Showcases Sustained Organic Growth, Margin Expansion, Oppenheimer Says](https://longbridge.com/en/news/280678877.md)